Race is not associated with nevirapine pharmacokinetics

Therapeutic Drug Monitoring

Volumn 26, Issue 4, 2004, Pages 456-458

  De Maat, Monique M R ^a   Nellen, Jeannine F J B ^b   Huitema, Alwin D R ^a   Wit, Ferdinand W M N ^b,c   Mulder, Jan W ^a   Prins, Jan M ^b   Beijnen, Jos H ^a,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Intl Antiviral Ther Eval Center   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Nevirapine; Pharmacokinetics; Race

Indexed keywords

ASPARTATE AMINOTRANSFERASE; EFAVIRENZ; NELFINAVIR; NEVIRAPINE;

ADULT; AGE; AMBULATORY CARE; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CAUCASIAN; COMPUTER PROGRAM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; FEMALE; GENDER; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEGRO; NETHERLANDS; PHARMACOGENETICS; PRIORITY JOURNAL; RACE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-HIV AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DATABASES, FACTUAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; NONLINEAR DYNAMICS; RETROSPECTIVE STUDIES;

EID: 3342931051     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200408000-00018     Document Type: Article

References (17)

1. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
2. Veldkamp AI, Weverling GJ, Lange JMA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 2001;15:1089-1095.
3. Sowunmi A, Rashid TJ, Akinyinka OO, et al. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br J Clin Pharmacol. 1995;40:489-493.
4. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′-promotor region polymorphism. Clin Pharmacol Ther. 2000;68:82-91.
5. Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002;12:121-132.
6. Hetherington S, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir: retrospective analysis of 25 clinical trials. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 8-11, 2001; abstract 527.
7. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002; 359:1121-1122.
8. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet. 2002;359:727-732.
9. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34: 1137-1142.
10. De Maat MMR, Huitema ADR, Mulder JW, et al. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol. 2002;54:378-385.
11. Van Heeswijk RPG, Hoetelmans RMW, Meenhorst PL, et al. Rapid determination of nevirapine in human plasma by ion-pair reversed phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B. 1998;713:395-399.
12. Beal SL, Sheiner LB. NONMEM User's Guide, NONMEM Project Group, University of California at San Francisco, 1998.
13. De Maat MMR, Ekhart GC, Huitema ADR, et al. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet. 2003;42:223-282.
14. Erickson DA, Mather G, Trager WF, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999;27: 1488-1495.
15. Kinirons MT, Lang CC, He HB, et al. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. Br J Clin Pharmacol. 1996;41:69-72.
16. Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups. Clin Pharmacol Ther. 2001;69:24-31.
17. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359: 30-36.